We used our recently validated quantitative, convenient, highly reproducible PLA2 assay method [16] and showed for the first time that plasma PLA2 activities from patients with CRC, LC, PC, and bladder cancer (BC) were significantly higher than those of healthy controls. The gene discussed is PLA2G6; the disease is pachyonychia congenita.